Array BioPharma Inc. (ARRY) escalated 5.62% and closed its last trading session at $10.53. Its opening price on the last trading day was $9.97. The company’s market cap is $1.6 Billion. The company has 160.36 Million shares outstanding and 160.36 Million shares were floated in market. The short ratio in the company’s stock is documented at 5.99 and the short float is around of 13.32%. Array BioPharma Inc. has been given an analysts’ mean target of 12.5.
The highest price ARRY stock touched in the last 12 month was $13.4 and the lowest price it hit in the same period was $3.45. Stock’s distance from 52 week High is -21.42% and the distance from 52 week Low is 207.89%.
Share Volume Analysis
A total of 6.13 Billion shares exchanged at hands and its average trading volume is standing at 3.56 Million shares. The relative volume of the stock is 1.72.
Array BioPharma Inc. (ARRY) performance during the last one year upgraded 176.18 percent, while its year to date (YTD) performance showed a positive trend of 13.42 percent. The stock fell -9.36 percent over the past six months. The stock’s quarterly performance indicates a positive momentum of 27.17 percent, whereas its last one month trend is optimistic with 15.66 percent. Its weekly performance showed upward trend of 1.73 percent.
Profit Margins Analysis
Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at -77.4 percent, operating profit margin was -68.6 percent, while gross profit margin stands at 76.5 percent.
Key Ratios Review
Liquidity ratios help investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 3.9, current ratio was 3.9, LT Debt/Equity ratio was 11.44 and Total Debt/Equity ratio stands at 0, while Payout ratio is 0.
Return on Assets, Investment and Equity
Array BioPharma Inc. (ARRY) has a Return on Assets of -48 percent, Return on Investment of -71.1 percent and a Return on Equity of 0 percent.
Simple Moving Average
Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Now we look at the Moving Averages, the 200-day is 15.41%, the 50-day is 20.63% and the 20-day is 10.28%.
EPS Growth Analysis
The company’s diluted EPS for trailing twelve months was -0.72.
EPS Estimate for the next year is -0.36.
EPS Estimate for the next Quarter is -0.23.
EPS Growth this year is -10.2 percent.
Earnings and Sales Growth
EPS growth for the next 5 years is 10 percent.
Annual EPS growth Past 5 years is -16.5 percent.
Annual Sales Growth in the past 5 years was 12.1 percent.
Quarterly Revenue Growth on year-over-year basis stands at -21.8 percent.
Quarterly Earnings Growth on year-over-year basis stands at 0.6 percent.
Investment Valuation Ratios
The company P/E (price to earnings) ratio is 0 and Forward P/E ratio is 0. The company P/S (price to Sales) ratio is 10.6, P/B (price to Book) ratio is 142.43, while its P/C (price to Cash) ratio stands at 6.82.
If we look at the Volatility of Array BioPharma Inc. (ARRY), Week Volatility is 12.23%, whereas Month Volatility is at 6.87%.
Array BioPharma Inc. (ARRY)’s RSI (Relative strength index) is at 61.13, its ATR (Average True Range) value is 0.73, while its Beta factor was calculated at 2.11.
Earnings Released Date
The company last reported its quarterly results on Aug 09 BMO.
Array BioPharma Inc. (ARRY) has an Analysts’ Mean Recommendation of 1.8.
Insider Ownership and Transactions
Array BioPharma Inc.’s insider ownership stands at 0.3 percent, while its insider transaction is -12.7 percent.
Institutional Ownership and Transactions
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Array BioPharma Inc.’s institutional ownership is 0%, while its institutional transactions stand at 1.07%.